The room-temperature collagen pad, approved for hemostasis and sealing, features an extended shelf life of three years. It involves the interaction of two components that can create rapid and lasting hemostasis by sealing off the bleeding surface.
Preclinical studies have shown that patch resorption and replacement with host tissue takes place within about six to eight weeks, according to Baxter.
Steve Wallace, president of Advanced Surgery at Baxter, explained in a promotional video that Baxter created and tested over 400 prototypes before it launched the latest version of Hemopatch. The patch was originally launched in 2013 as a hemostatic patch and received its sealing indication in 2016.
Hemopatch has a white, tissue-facing side covered with a thin layer of NHS-PEG. When in contact with blood or other body fluids, NHS-PEG forms a hydrogel. This enhances its adhering properties and seals the tissue surface. In contact with blood, collagen induces aggregation of platelets. Platelets deposit in large numbers on the collagen structure, degranulate and release coagulation factors. Together with plasma factors, this enables the formation of fibrin.
Hemopatch’s structure provides a three-dimensional matrix that readily absorbs fluids, according to Baxter. It provides additional mechanical strengthening of the clot, too. Baxter says its Hemopatch sealing hemostat has multiple clinical benefits, such as sealing tissue, stopping and preventing leaks, fast and effective hemostasis within 2 minutes and being absorbed and replaced by host tissue.
Wallace said in a news release: “Hemopatch sealing hemostat represents a significant development from Baxter, and introducing the room-temperature variant highlights our ongoing dedication to innovation in tissue management.”
